drugset
drugset / Trial / NCT05460533

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

NCT05460533 ↗

Phase 2 Active not recruiting 30 enrolled Memorial Sloan Kettering Cancer Center Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.

Timeline

Start
2022-07-12
Primary completion
2027-07
Completion
2027-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisagenlecleucel Cell therapy — —

Indications

B-cell acute lymphoblastic leukemia